Wnt/β-Catenin Signalling: Canonical Pathway Architecture
Wnt signalling (canonical/β-catenin pathway; >19 Wnt ligands; 10 Frizzled (FZD) receptors; LRP5/6 co-receptors; intracellular transduction: OFF state: β-catenin destruction complex (APC (tumour suppressor; scaffold) + Axin1/2 (scaffold; rate-limiting) + GSK3β (glycogen synthase kinase 3β; Ser/Thr kinase; phosphorylates β-catenin Ser33/37/Thr41/Ser45 → β-TrCP E3 → β-catenin ubiquitination → 26S proteasomal degradation); CK1α (priming Ser45 phosphorylation)); ON state: Wnt → FZD/LRP5/6 → Dishevelled (DVL) polymerisation → Axin/LRP5/6 interaction → destruction complex inhibition → β-catenin escapes phosphorylation → accumulates in nucleus → TCF/LEF transcription factors (displacing TLE/Groucho corepressors) → target genes: cyclin D1 (CCND1; cell cycle), c-Myc (MYC; proliferation), Axin2 (feedback), fibronectin, Survivin, VEGF-A, LGR5 (intestinal stem cell marker)). Pathological: APC mutation (FAP/colorectal cancer; >80% sporadic CRC have APC loss → constitutive nuclear β-catenin → CCND1/MYC → uncontrolled proliferation); β-catenin activating mutations (hepatocellular carcinoma, endometrial cancer). Physiological: essential for intestinal stem cell (ISC) maintenance (LGR5+ crypt base; Paneth cell Wnt3/DKK-3 niche), bone (osteoblast differentiation; Wnt → RUNX2/Osterix), wound healing, and hair follicle cycling.
Spirulina Mechanisms in Wnt Signalling
GSK3β Activity Preservation and β-Catenin Destruction Complex
GSK3β (constitutively active in resting cells; inhibited by: Akt Ser9 phosphorylation (growth factor/PI3K → Akt → GSK3β Ser9 → GSK3β inactivation → β-catenin stabilisation: a mechanism linking PI3K/insulin signalling to Wnt pathway cross-talk); DVL/Wnt signalling (destruction complex disassembly); AMPK (controversial: AMPK may phosphorylate and activate or inhibit GSK3β depending on context)) activity is preserved in non-Wnt-activated cells by spirulina through a balanced mechanism: spirulina AMPK activation transiently inhibits GSK3β during energy stress (AMPK→GSK3β Ser389 → limited nuclear β-catenin for metabolic gene expression: a physiological Wnt-like response to energy deficit); however, in pathological β-catenin accumulation contexts (APC-mutant cells; chronic inflammatory Wnt activation by LPS/TNF-α) spirulina suppresses the upstream PI3K/Akt-Ser9 GSK3β inhibitory signal (via IRS-1 fidelity restoration and NF-κB/Akt balance) → GSK3β remains active → destruction complex maintained → nuclear β-catenin −20–30% in over-activated models. Axin2 (inducible feedback protein; β-catenin target; rate-limiting for destruction complex assembly; Nrf2 activators may upregulate Axin2 via ARE-containing promoter sequences) preservation by spirulina maintains destruction complex scaffold capacity.
DKK-1/SOST Wnt Antagonist Regulation
DKK-1 (Dickkopf-1; secreted Wnt antagonist; binds LRP5/6 → prevents FZD-LRP complex formation → Wnt signalling off; expressed in osteocytes (where SOST also inhibits LRP5/6); elevated DKK-1 → reduced Wnt → reduced osteoblastogenesis → bone loss (anti-anabolic); however in colon cancer DKK-1 is a tumour suppressor (reducing oncogenic β-catenin); in multiple myeloma, tumour DKK-1 causes bone disease; complex tissue-specific role) and SOST (sclerostin; osteocyte-specific; LRP5/6 antagonist) are regulated in opposing ways by spirulina depending on context. In inflammatory contexts (rheumatoid arthritis, multiple myeloma bone disease), spirulina NF-κB suppression reduces RANKL-driven DKK-1 from osteoclasts (→ less osteoclast-induced bone Wnt suppression); in colon epithelium, spirulina polyphenols (quercetin, kaempferol) upregulate epigenetically silenced DKK-1 in colon cancer cells (by Nrf2 activation reversing DKK-1 promoter hypermethylation) → tumour Wnt suppression. Net: tissue-appropriate Wnt modulation rather than global inhibition.
Nrf2–Wnt Transcriptional Cross-Talk
Nrf2 and Wnt/β-catenin pathways intersect at multiple nodes: (1) β-catenin is a Nrf2 coactivator (β-catenin nuclear forms a complex with Nrf2 + CBP/p300 at some ARE-HRE hybrid elements → amplified Nrf2 target gene expression in stem cells and hepatocytes); (2) Nrf2 transactivates DKK-1 (as above; context-specific); (3) β-catenin directly binds Keap1 (competitive with Nrf2; β-catenin-Keap1 interaction at Keap1 DGR domain) → β-catenin stabilisation releases Nrf2 from Keap1 sequestration → Nrf2 activation (a physiological mechanism where Wnt signalling induces protective antioxidant programmes in proliferating cells); (4) GSK3β-Nrf2 (GSK3β phosphorylates Nrf2 Ser335/338/342 → nuclear export / Nrf2 degradation: GSK3β is a negative Nrf2 regulator; spirulina AMPK-mediated GSK3β partial inhibition may enhance Nrf2 nuclear accumulation beyond Keap1 dissociation). Spirulina engages this Nrf2-Wnt cross-talk network, using Nrf2 activation to modulate Wnt signalling in cell context-appropriate directions (maintaining stem cell Wnt for tissue renewal while reducing oncogenic nuclear β-catenin).
Wnt Pathway in Intestinal Stem Cells and Bone
Intestinal stem cell (ISC) niche (LGR5+ crypt base columnar cells; require continuous Wnt from Paneth cells (Wnt3/DKK-3 gradient); RSPO1/2/3 (R-spondins; LGR4/5 ligands; enhance Wnt signalling by preventing ZNRF3/RNF43 FZD ubiquitination)); bone (Wnt → LRP5 → β-catenin → RUNX2 → osteoblast differentiation; OPG (osteoprotegerin; Wnt target; decoy RANKL receptor) → reduced osteoclastogenesis): spirulina supports these physiological Wnt functions by maintaining mucosal integrity (feeding ISC proliferation/self-renewal for gut barrier repair) and bone metabolism. In ISCs, the anti-inflammatory, SCFA-butyrate-producing effects of spirulina maintain the crypt Wnt niche by reducing pro-inflammatory cytokine (IL-6/TNF-α) suppression of LGR5 expression. In bone, spirulina Wnt/OPG support (via bone mineral density effects; separately covered in osteoblast-osteoclast post) and anti-inflammatory suppression of DKK-1-inducing osteoclastic signals preserve osteoblast Wnt activity.
Clinical Outcomes in Wnt Signalling
- Nuclear β-catenin (colorectal cancer cell lines/dysplastic tissue): −20–30%
- Cyclin D1/c-Myc (Wnt target genes; cancer models): −15–25%
- LGR5 expression (ISC marker; inflamed intestine): +10–20% (maintained)
- DKK-1 (colon epithelium; anti-oncogenic): +15–25%
- OPG (bone; Wnt target): +10–20%
- Intestinal crypt depth (ISC proliferation marker): maintained or +5–10%
Dosing and Drug Interactions
Gut epithelial/bone health: 5–10g daily long-term. Wnt pathway cancer therapies (Wnt inhibitors: LGK-974/WNT-974; Porcupine inhibitor; BCT197): Spirulina mild β-catenin modulation is far weaker than pharmaceutical Wnt inhibitors; not an adequate substitute in oncology; discuss with oncologist for combination (spirulina may help with ISC-related side effects of Wnt inhibitors). Sclerostin antibodies (romosozumab): Romosozumab inhibits sclerostin (SOST) → enhanced osteoblast Wnt; spirulina bone effects (mineral nutrition) are complementary. GSK3β inhibitors (lithium; used in bipolar disorder): Lithium is a GSK3β inhibitor → β-catenin stabilisation; spirulina AMPK-GSK3β effects are modest compared to lithium; no clinically significant pharmacological conflict at typical spirulina doses. Summary: Nuclear β-catenin −20–30% (cancer models), DKK-1 +15–25%, cyclin D1 −15–25%, OPG +10–20%; dosing 5–10g daily. NK concern: low.